Never miss a story with The Brief, our free newsletter.
Independent Texas reporting needs your support. Help us bring you and millions of others in-depth news and information. Will you join our nonprofit newsroom with a donation of any amount?
We go where the story is
The Brief, our morning newsletter, turns what our reporters see and hear across the state into what you should know.
About The Texas Tribune | Staff | Contact | Send a Confidential Tip | Ethics | Republish Our Work | Jobs | Awards | Corrections | Strategic Plan | Downloads | Documents
Our reporting on all platforms will be truthful, transparent and respectful; our facts will be accurate, complete and fairly presented. When we make a mistake — and from time to time, we will — we will work quickly to fully address the error, correcting it within the story, detailing the error on the story page and adding it to this running list of Tribune corrections. If you find an error, email corrections@texastribune.org.
By Polo RochaRepublish our articles for free, online or in print, under a Creative Commons license.
Take our content — please! — You’re welcome to republish this article for free as long as you follow our republishing guidelines, which includes using our canonical URL and pixel tracker on your story pages whenever possible.
by Polo Rocha, The Texas Tribune
August 3, 2015
Federal regulators have signed off on a new drug that lowers cholesterol, a development that could bring an important but costly new medical tool to fighting heart disease. The drugs — which could benefit millions — are an alternative to the much-cheaper statins, the common cholesterol-lowering drug that might not be adequate for some. (Wall Street Journal)
Learn about The Texas Tribune’s policies, including our partnership with The Trust Project to increase transparency in news.
